Given Imaging and Olympus settle patent suit

The firms will cross license future capsule endoscopy products.

Given Imaging Ltd. (Nasdaq: GIVN; TASE: GIVN) and Olympus Corporation (TSE: 7733; DAX: OLY; Pink Sheets: OCPNY) have signed a term sheet to settle their patent lawsuit in US over their capsule endoscopy products.

The term sheet includes certain worldwide cross-licenses under which each party receives a royalty-free license under all existing patents of the other party for its respective existing capsule endoscopy products. The parties also exchanged covenants not to sue on currently available medical device products and agreed to a release of all past causes of action. The term sheet also includes a cross-license under existing and future patents of each party for future capsule endoscopy products, which may include the payment of royalties by either party at a rate to be determined through an agreed upon mechanism. Finally, the term sheet includes a payment to Given Imaging of $2.33 million and an agreement to cooperate in future mutually beneficial joint market development projects.

The settlement will become final upon the signing of a formal written agreement, which is currently being prepared and is expected to be signed as soon as possible. In the interim, the parties have agreed to ask the court to stay all activity in the pending litigation. Following signing of the formal agreement, the parties will submit to the court a request for dismissal of the lawsuit. All other terms and conditions are confidential.

Given Imaging says it plans to update its fiscal year 2008 earning per share guidance when it releases its financial report for the first quarter of 2008 on May 13. the rose share 0.2% in morning trading on the TASE today. The share is down 42.8% since the beginning of the year.

Published by Globes [online], Israel business news - www.globes-online.com - on April 21, 2008

© Copyright of Globes Publisher Itonut (1983) Ltd. 2008

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters